Pfizer Inc. PFE

28.67 0.26 0.92% as of 25 Sep
Market cap
$161.7B
P/E
37.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Pfizer Inc. (PFE) Revenue growth

Pfizer Inc.'s revenue growth over the twelve months to 30 June 2026 was −0.21%, up 1.4 percentage points from fiscal 2025 (−1.65%). Over the past ten years it has ranged from −41.1% (fiscal 2023) to 95.2% (fiscal 2021); the current reading is higher than 27% of that period. That is below the Drug Manufacturers General industry median of 6.79% and below the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 −1.65% (8.49)
FY2024 6.84% 47.98
FY2023 −41.1% (65.60)
FY2022 24.5% (70.70)
FY2021 95.2% 93.34
FY2020 1.82% 1.62
FY2019 0.20% 22.51
FY2018 −22.3% (21.78)
FY2017 −0.53% (8.66)
FY2016 8.13% 9.65

Quarterly

Period Revenue growth Change (points)
Jun 2026 2.60% (2.77)
Mar 2026 5.37% 6.53
Dec 2025 −1.16% 4.76
Sep 2025 −5.92% (16.23)
42 more quarters

Against its own ten years

Low −41.1% High 95.2%
Ten-year median 0.20%
Current reading's percentile 27

Revenue growth against peers

Company Revenue growth
SNY Sanofi compare 21.3%
NVO Novo Nordisk A/S compare 13.2%
AMGN Amgen Inc. compare 9.10%
GSK GSK PLC Sponsored ADR compare 8.72%
AZN AstraZeneca PLC compare 8.61%
GILD Gilead Sciences, Inc. compare 5.52%
BMY Bristol Myers Squibb Company compare 3.11%
NVS Novartis AG compare 2.73%
PFE Pfizer Inc. −0.21%
Drug Manufacturers General industry median 6.79%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on PFE